Combating the Opioid Crisis With Smarter Federal Spending

In November 2021, the CDC released provisional data showing that the U.S. had surpassed 100,000 drug overdose deaths in a 12-month period. At the same time, federal spending on opioid-related programs has been at an all-time high, with approximately $6.6 billion appropriated in FY2022, and significantly greater expenditures through the Medicaid and Medicare programs. With treatment options still out of reach for many Americans and overdoses from fentanyl and synthetic opioids climbing, policymakers remain unsure whether recent investments in opioid-related programs are having an impact.

Please join BPC on Monday, May 2 from 1-2 p.m. ET for a discussion on new recommendations focused on optimizing federal spending and improving the federal response to the opioid epidemic.

Keynote remarks:

Rahul Gupta, MD, MPH
Director, Office of National Drug Control Policy

Congressional remarks:

Joe Manchin
U.S. Senator, West Virginia

Panel discussion:

Jerome Adams, MD
20th U.S. Surgeon General; Presidential Fellow, Executive Director of Purdue University’s Equity Initiatives, and Distinguished Professor of Practice

Mary Bono
Former U.S. Representative, California

Patrice Harris, MD, MA
CEO, eMed; Former President, American Medical Association

Donna E. Shalala, PhD
Former Secretary, U.S. Department of Health and Human Services; Former U.S. Representative, Florida

Moderated by:

Karen Scott, MD, MPH
President, Foundation for Opioid Response Efforts

Additional participants to be announced